For appropriate patients on a multi-tablet darunavir regimen
Simplify the regimen with SYMTUZA®
SYMTUZA® is the only STR formulation of darunavir and the smallest darunavir coformulation available1-3
(Pills Are Not Actual Size)
Switch Darunavir Patients to SYMTUZA®
Simplify the regimen with SYMTUZA®
Access, affordability, and treatment support for your patients
~90% of patients nationwide have coverage for SYMTUZA®2*
The convenience of just one co-pay for SYMTUZA®
Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help patients start and stay on SYMTUZA® that you prescribed
SYMply Start® Trial Offer
Free 30-day trial supply
SYMply Start® Trial Offer from Janssen CarePath offers eligible patients a free 30-day trial supply of SYMTUZA® to help your patient determine if SYMTUZA® is right for them. Patients must be 12 years of age or older and have a valid, signed 30-day prescription. At the conclusion of the program, you and your patient decide if it is appropriate to continue treatment. Terms expire at the end of each calendar year and may change. This Trial Offer is open to patients who have commercial insurance, government coverage, or no insurance coverage; however, there is no guarantee of continuous accessibility after the program ends. Please refer to the SYMply Start® Trial Offer brochure for program requirements or call Janssen CarePath at
877‑CarePath (877-227-3728) to get a Trial Offer card for your patient.
Patients can begin the registration process by simply texting “VOUCHER” to 41949 (message and data rates may apply†). Once registered, patients will receive an electronic version of the Trial Offer card that can be saved to their digital wallet on their iPhone or Android device.
Janssen CarePath Savings Program
Support for patients using commercial or private insurance to pay for medication
Janssen CarePath Savings Program can help eligible patients save on their out-of-pocket costs for SYMTUZA®. Depending on their health insurance plan, savings may apply toward co-pay, co-insurance, or deductible. Your eligible patients will pay $0 per prescription fill, with a $12,500 maximum program benefit per calendar year. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement.
See full eligibility requirements.
Express Enrollment at JanssenCarePathPortal.com/express
Providers can check patients’ eligibility and enroll eligible patients in the Janssen CarePath Savings Program with no Business Associate Agreement (BAA) required.
Patients can enroll by texting “SAVINGS” to 89633 (message and data rates may apply†) or using Express Enrollment at MyJanssenCarePath.com/express
- Patients can receive an electronic Savings Program card that can be saved to their digital wallet on their iPhone or Android device
*This percentage may not represent 100% of formulary lives due to data limitations.
†Terms and Privacy Policy can be found at JanssenCarePath.com/Terms-Conditions-Mobile and JanssenCarePath.com/Privacy-Policy.
DRV=darunavir; NRTI=nucleoside reverse transcriptase inhibitor; TAF=tenofovir alafenamide; STR=single tablet regimen.
Collected in 13-Apr and may change.
This information does not give advice or promise coverage or payment. Legal requirements and plan information can be updated frequently. Contact the plan for more information about current coverage, restrictions, or requirements that may apply.
References: 1. SYMTUZA® [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP. 2. Source: Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of mm/yy. 3. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated January 20, 2022. Accessed March 8, 2022. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines